The Genome Analysis Core provides services and advice for DNA sequencing, genotyping, and gene expression analysis. The DNA sequencing services are instrumental in helping scientists determine causative mutations in the germline or somatic genes which lead to certain cancers or human diseases. DNA sequencing services are also used to interrogate the methylation status of genes. Loss of heterozygosity (LOH) and genetic linkage analyses are used for identifying regions of the genome likely to be involved in the occurrence and progression of malignancies. The Core has extensive experience performing micrbsatellite and single base extension SNP genotyping on the 3700 platform, and TaqMan allelic discrimination SNP typing on the 7900HT platform for these purposes. The sequencing capability is also used to determine whether there are exon-sized deletions in one allele of a cancer susceptibility gene once it has been determined that there are no point mutations. For these studies, the sequencer is used to analyze fluorescent fragments generated by the Multiplex Amplifiable Probe Hybridization (MAPH) or Multiplex Ligation-dependent Probe Amplification (MLPA), and Spectratyping techniques. A major focus of the Core's services is the use of quantitative real-time PCR (Q-PCR) on the 7900HT platform. Using an arsenal of TaqMan assays, the Core provides services for DNA copy number measurements and mRNA expression analyses, plus training courses for members of the Cancer Center to learn Q-PCR techniques. The Cancer Center Genome Analysis Core works to improve access of Cancer Center member to genetic and genomic technologies. The services from we offer, or propose to develop, are actively coordinated with the other UCSF genomics core facilities to avoid detrimental duplication of capacity. For example, Cancer Center members have access to extensive high throughput gene expression and genotyping technology (Affymetrix and Illumina) through core facilities at the Parnassus and Mission Bay campuses of UCSF.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-10
Application #
7619934
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
10
Fiscal Year
2008
Total Cost
$287,050
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28

Showing the most recent 10 out of 192 publications